Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$81,757.00-1.80%ETH$2,473.27-3.71%GOLD$4,160.60+0.09%OIL$90.99-0.55%
Smart Investors Daily
SID Premium
SE

NASDAQ · SER

Serina Therapeutics, Inc.

Healthcare · Biotechnology

$2.01

Up+$0.00 (+0.00%)

Updated Oct 8, 2026, 10:30 PM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
33.49M
P/E ratio
-2.49
Dividend yield
0.00%
52-week range
$1.22 – $3.29
Volume
13.18K
Avg. volume
27.05K

Price performance · SER

SER price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

SER closed at $2.01 after 21 trading sessions, down 21.79% for the selected period.

Last close
$2.01
Period change
-21.79%
Period low
$1.95
Period high
$2.57
Daily close
View OHLC price history
SER OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$2.04$2.08$2.01$2.0113.18K
Oct 6, 2026$2.025$2.0796$2.0162$2.048.72K
Oct 5, 2026$2.10$2.10$1.9651$2.0425.27K
Oct 2, 2026$1.98$2.10$1.9517$1.9615.57K
Oct 1, 2026$1.96$2.06$1.95$1.9546.77K
Sep 30, 2026$2.09$2.09$2.00$2.0010.86K
Sep 29, 2026$1.97$2.1299$1.97$2.0815.78K
Sep 28, 2026$2.08$2.20$2.00$2.011.02M
Sep 25, 2026$2.13$2.1969$2.09$2.0929.45K
Sep 24, 2026$2.19$2.2982$2.14$2.1476.45K
Sep 23, 2026$2.30$2.315$2.17$2.198.95K
Sep 22, 2026$2.28$2.4295$2.16$2.3123.85K
Sep 21, 2026$2.15$2.3709$2.00$2.3130.98K
Sep 18, 2026$2.20$2.29$2.0865$2.2566.09K
Sep 17, 2026$2.26$2.31$2.18$2.2230.04K
Sep 16, 2026$2.35$2.35$2.16$2.1621.48K
Sep 15, 2026$2.46$2.47$2.25$2.3531.88K
Sep 14, 2026$2.35$2.5499$2.28$2.4574.52K
Sep 11, 2026$2.41$2.54$2.20$2.2269.31K
Sep 10, 2026$2.55$2.58$2.3601$2.5068.83K
Sep 9, 2026$2.75$2.78$2.35$2.57404.46K

Latest SER news

The latest Smart Investors Daily articles mentioning SER.

Stock researchCompany · Overview

SER research

Overview

Company profile and research snapshot.

Company profile

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
SER recent ratings
DateFirmRatingTarget
Sep 10, 2026BTIGBuy—
Jul 1, 2026BTIGBuy—
Aug 28, 2025HC Wainwright & Co.Buy—
Jul 14, 2025HC Wainwright & Co.Buy—
Mar 11, 2025Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 24, 2026

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will hold virtual one-on-one investor meetings on Wednesday, July 29, 2026. Please contact your BTIG representative to reques

Yahoo · Jul 23, 2026

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol - - Company expects to provide a further update following completion of the Safety Monitoring Committee review – HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a c

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By